Previous Close | 127.1 |
1-Year Change | 151.53% |
6-Months Change | 36.81% |
3-Months Change | 18.56% |
Moving Avg (50d) | 113.66 |
Moving Avg (200d) | 92.6 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 15.1B |
Beta (3-Years) | 1.5 |
Revenue Growth (ttm) | 27.41% |
Net Profit Margin (ttm) | -50.5% |
Return On Assets (ttm) | -34.52% |
EPS (ttm) | -4.52 |
PE Ratio (ttm) | -28.12 |
Dividend Yield | % |
Asset Description: | Natera, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-07-17 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
129.642 | 133.455 | 135.997 | 139.81 | 146.165 | 152.52 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Life Sciences Tools & Services |
Country: | United States |
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited... Wikipedia